Blue Mountain Technologies

medical devices
diagnostics
reagent

Blue Mountain Technologies is an internal enterprise, managed by Mount Sinai Innovation Partners, responsible for bringing Mount Sinai’s growing portfolio of diagnostics, medical devices, and research tools to market through commercial partnerships.

Contact Us

Products

Research Reagents: Antibodies
CloneTargetImmunogenIsotypeReactivityIHCWestElisa
12F4Beta-amyloid 42Beta-amyloid 42 C-term., and specific for isoform ending at the 42nd amino acidIgG1Human and mouse YYY
9C4Beta-amyloid 43Beta-amyloid 43 C-term., and specific for isoform ending at the 43rd amino acidIgG1Human and mouse YYY
11A50-B-10Beta-amyloid 40Beta amyloid 40 C-term., and specific for isoform ending at the 40th amino acidIgG1Human and mouse YYY
2A9PLZFHuman PLZF - GST fusion proteinIgG2aHuman and mouseWest, IP and IF
35D5LRP5Cytoplasmic domain of LRP5IgG1Human and mouseWest and IP
1C10LRP6Cytoplasmic domain of LRP6IgG1Human and mouseWest and IP
29D1WHSC1/NSD2Human WHSC1/NSD2 - GST fusion protein, a.a. 1-647 human GSTIgG2aHumanY
17C2IRF3Human IRF3 C-terminal region recombinant proteinIgG2aHumanWest and IFY
6B3EKLFMouse EKLF (KLF1)IgG1Human and mouse Y
7B2EKLFMouse EKLF (KLF1)IgG3Human and mouse Y
24 E6BRCA1Human BRCA1 a.a .1600-1749IgG2bHumanWest, IP and IF
17B5NPC1Human NPC-1 fragment conjugated to a carrier proteinIgG1HumanY
1C3RIG-IIgG1HumanWest and IP
9A2KLF6 (splice variant 1)Human KLF6 splice variant 1 recombinant proteinIgG2aHuman Y Y Y
2A2KLF6Human KLF6 synthetic peptideIgG2aHuman Y Y
22B3RNF5 Human full length recombinant RNF5IgG1Human and mouse Y
3D11Advanced Glycation Endproducts(AGE)-MGMethylglyoxal-modified ovalbumin (OA) Y Y Y
3A11GluR2, 4Recombinant fusion protein trpE-GluR2IgG2aHuman, monkey and ratYYY
A32-F8NMDAR2AHuman NMDA2A fusion proteinMouseYYY
A3-2D10NMDAR2AHuman NMDA2A fusion proteinIgG1Human, monkey, rat and canineYYY
A3-6B10NMDAR2AHuman NMDA2A fusion proteinMouseYYY
B3-13B11NMDAR2BHuman NMDA2B fusion proteinIgG1Human, monkey, rat, canineYYY
3B3-A11GluR3Fusion protein encompassing the N-terminal region of the rat GluR3IgG1kHuman, monkey, ratYYY
5C4NMDA1a+d splice variantRat NMDA1 a+d fusion proteinMouseYYY
35A9Glutamate Transporter EAAC1Synthetic peptide corresponding to aa 161-177 of the rat glutamate transporter EAAC1 sequenceIgG2bHuman and ratYYY

Research Reagents: Other Reagents
MaterialDescriptionReferences
LX1 and LX2 cellsHepatic stellate cells (HSCs) are a major fibrogenic cell type that contributes to collagen accumulation during chronic liver disease. With increasing interest in developing antifibrotic therapies, there is a need for cell lines that preserve the in vivo phenotype of human HSCs to elucidate pathways of human hepatic fibrosis. We established and characterised two human HSC cell lines termed LX-1 and LX-2, and compared their features with those of primary human stellate cells. LX-1 and LX-2 human HSC lines provide valuable new tools in the study of liver disease. Both lines retain key features of HSCs. Two unique advantages of LX-2 are their viability in serum free media and high transfectability.Xu et al. Gut, 54, 142, 2005.
LSC cellsLSC cells are derived from LS174T human colonic cancer cells. LSC cells express only the truncated carbohydrate antigen Tn (GalNAca-Ser/Thr) and sialyl-Tn on their mucin molecules. LSC cells represent the first example of a non-hematopoietic cell line which lacks core 1 beta3-Gal-transferase activity, which is why they are incapable of forming the common mucin O-glycan core structures and are committed to synthesizing the short Tn and STn oligosaccharides. LSC cells provide a useful model for colon and other types of cancer.Brockhausen et al. Glycoconjugate Journal, 15, 595, 1998.
SOD-1 transgenic miceThese transgenic mice express a mutant form of the SOD-1 gene which contains the G86R missense mutation in exon 4 and is driven by the endogenous promoter. This mutation is prevalent in a subset of patients with familial amyotrophic lateral sclerosis (FALS).Ripps et al. PNAS, 93, 689, 1995
LRRK2-wt BAC mousePARK8/LRRK2 (leucine-rich repeat kinase 2) was recently identified as a causative gene for autosomal dominant Parkinson's disease (PD), with LRRK2 mutation G2019S linked to the most frequent familial form of PD. LRRK2-wt mice overexpress full-length LRRK2, have elevated striatal dopamine (DA) release with unaltered DA uptake and result in hyperactive mice with enhanced performance in motor function tests. This mouse is ideal for studying PD, especially when paired/contrasted with the LRRK2-G2019S BAC mouse.Li et al. J. Neurosci, 30, 1788, 2010.
LRRK2-G2019S BAC mousePARK8/LRRK2 (leucine-rich repeat kinase 2) was recently identified as a causative gene for autosomal dominant Parkinson's disease (PD), with LRRK2 mutation G2019S linked to the most frequent familial form of PD. LRRK2-G2019S mice contain the full-length LRRK2 BAC with the G2019S mutation and show an age-dependent decrease in striatal DA content, as well as decreased striatal DA release and uptake, providing a useful model for understanding early PD pathological events.Li et al. J. Neurosci, 30, 1788, 2010.
Floxed CREB1 mouseThese mice have LoxP sites spanning most of the coding region of the CREB1 gene. They are homozygous for this mutation and have been shown to support Cre-driven knockdown of CREB1 mRNA and protein. This mouse can be used to study the role of CREB, a ubiquitously expressed transcription factor, in diverse physiological functions in numerous organs and tissues in which CREB has been implicated.Cao et al. PNAS, 107, 17011, 2010
Viral Set recombinant proteinExpression vector for vSet. Viruses encode a conserved SET domain methyltransferase, termed vSET, that functions to suppress host transcription by methylating histone H3 at lysine 27 (H3K27), a mark for eukaryotic gene silencing.Wei et al. Proc Natl Acad Sci, 107, 18433, 2010.
NL4-3 HIV1 plasmidHIV-1 proviral clone expresses an internal GFP fusion and replicates in human T cell linesHubner et al. J Virol, 81, 12596, 2007.

Diagnostics
NameDescription
ClusterinAn ELISA that specifically tests for the presence of Clusterin, also known as apolipoprotein J (ApoJ), in the urine of human patients. This is the first test for determining who will develop renal impairment due to fibrosis following transplantation
SHROOM3 AssayA RNA screen for SHROOM3 expression levels, as well as SNP risk allele prevalence, in kidney allograft biopsies. SHROOM3 has emerged independently linked to incident and prevalent chronic kidney disease (CKD) in Caucasian predominant cohorts.
KLF6-sv1A mAb used to screen tumor biopsies for the presence of Krüppel-like family transcription factor 6, splice variant 1 (KLF6-sv1). KLF6-sv1 is potent driver of breast cancer metastasis and a prognostic marker for poor outcome in human breast cancer.
Melanoma recurrence assayA specialized RNA expression assay that uses Nanostring technology to predict melanoma reccurence and help physicians/patients decide on the use of imaging strategies and/or adjuvant therapies. Specially designed to be compatible with formadehyde-fixed, parrafin embedded clinical samples.

Devices
NameDescription
Endoluminal Keyhole TrocarA trocar with a keyhole cutout of one end, to be inserted into the lumen of a colostomy or ileostomy. It allows for the passage of a sharp needle through the wall of the bowel while protecting the opposite bowel wall.
E-Z Drill GuideA drill guide customized for the drilling of pilot holes and screw trajectories in a consistent and optimized way for a particular type of cervical instrumentation, known as the lateral mass screw technique.
Illness Warning InstrumentAn instrument that allows for the recording of 12 different items (behaviors) that can be tracked per patient over time. Empowers nursing assistants to relay vital information about acute changes in a patient's well-being aimed at early intervention in cases of acute illnesses.
Spinal Radiation ShieldAn implantable spinal radiation shield consisting of a thin flexible metallic film (0.1 - 0.2 mm thick) made from a dense but inert material like tantalum or gold, which protects the spinal cord from radiation injury while treating cancer with radiation therapy.
Magnetic Needle Retrieval InstrumentA minimally invasive, magnetic surgical device designed to fit through standard laparoscopic, robotic and endoscopic ports to retrieve lost metal surgical needles, clips, foreign bodies, etc.
Soft Tissue Sampling ToolA disposable, cylindrically-shaped soft tissue sampling tool that is 1-2 cm in diameter and >3 cm in height, specifically designed to perform standardized biopsies of soft, spongy and inconsistent tissues that are difficult to sample by using scalpels (placenta, brain, etc.).
Patch Trocar Site Closure DeviceAn "umbrella" type trocar site closure device consisting of small ridges and bristles on the back of the umbrella that allow it to be anchored into the peritoneal lining so that it patches the actual trocar hole preventing any herniation of bowel contents.
Ventilation Bag Microbial SheathAn impermeable, synthetic sheath covered ventilation bag that comes pre-sealed and can be incorporated/used with disposable anesthesia circuits. Reduces liklihood of patient-derived cross contamination during intubation.

 

Success Story

In 2009 Edwards Life Sciences launched a new mitral valve repair ring called the Carpentier-Edwards Physio II. Dr. David H. Adams at Mount Sinai, one of the leading mitral repair authorities in the world, is an inventor of this next-generation mitral valve repair ring. The Physio II is the only annuloplasty ring offering shape optimization, which matches the geometry of the ring to the characteristics of the patient’s diseased mitral valve, and does not limit repair options based on etiology, or cause, of the mitral valve disease. Mount Sinai and Edwards entered into a royalty bearing agreement in 2007 for the transfer of intellectual property invented by Dr. Adams which has been incorporated into the Physio II ring.